681
Views
4
CrossRef citations to date
0
Altmetric
Oncology

Characteristics and treatment patterns of relapsed/refractory diffuse large B-cell lymphoma in patients receiving ≥3 therapy lines in post-CAR-T era

, , , , , & show all
Pages 1789-1798 | Received 05 May 2021, Accepted 15 Jul 2021, Published online: 17 Aug 2021

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (1)

Maryia Zhdanava, Jacqueline Pesa, Porpong Boonmak, Qian Cai, Dominic Pilon, Zia Choudhry & Nizar Souayah. Economic burden of generalized myasthenia gravis (MG) in the United States and the impact of common comorbidities and acute MG- events. Current Medical Research and Opinion 0:0, pages 1-12.
Read now

Articles from other publishers (3)

Anna Guarini, Giulia Radice, Nadia Peragine, Chiara Buracchi, Maria Stefania De Propris, Alice Di Rocco, Arianna Di Rocco, Sabina Chiaretti, Alex Moretti, Sara Napolitano, Maurizio Martelli, Adriana Balduzzi, Giuseppe Gaipa, Andrea Biondi & Robin Foà. (2023) Long-Term Host Immune Modulation Following Tisagenlecleucel Administration in Patients with Diffuse Large B-Cell Lymphoma and B-Lineage Acute Lymphoblastic Leukemia. Cancers 15:9, pages 2411.
Crossref
Mehdi Hamadani, Laura Liao, Tony Yang, Lei Chen & Craig Moskowitz. (2022) Characteristics and Clinical Outcomes of Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma Who Received At Least 3 Lines of Therapies. Clinical Lymphoma Myeloma and Leukemia 22:6, pages 373-381.
Crossref
Jessica J. Jalbert, Ning Wu, Chieh-I Chen, Srikanth Ambati, Wenzhen Ge & Jon E. Arnason. (2022) Real-World Treatment Patterns After CD19-Directed CAR T Cell Therapy Among Patients with Diffuse Large B Cell Lymphoma. Advances in Therapy 39:6, pages 2630-2640.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.